國立虎尾科技大學 |

Advances in Host-Directed Therapies Against Tuberculosis

紀錄類型:	書目-語言資料,印刷品 : Monograph/item
正題名/作者:	Advances in Host-Directed Therapies Against Tuberculosis / edited by Petros C. Karakousis, Richard Hafner, Maria Laura Gennaro.
其他作者:	Gennaro, Maria Laura.
面頁冊數:	XIII, 332 p. 20 illus.online resource. :
Contained By:	Springer Nature eBook
標題:	Infectious Diseases. -
電子資源:	https://doi.org/10.1007/978-3-030-56905-1
ISBN:	9783030569051

Advances in Host-Directed Therapies Against Tuberculosis
Advances in Host-Directed Therapies Against Tuberculosis [electronic resource] /edited by Petros C. Karakousis, Richard Hafner, Maria Laura Gennaro. - 1st ed. 2021. - XIII, 332 p. 20 illus.online resource.

Section 1: Introduction -- Chapter 1: Introduction: An overview of host-directed therapies for tuberculosis -- Section 2: Targeting immunometabolism -- Chapter 2: Sirtuin deacetylases: Linking Mycobacterial infection and host metabolism -- Chapter 3:The mammalian target of rapamycin complex 1 (mTORC1): an ally of M. tuberculosis in host cells -- Chapter 4: HIF-1α as a potential therapeutic target for tuberculosis treatment -- Chapter 5: Nuclear receptors in host-directed therapies against tuberculosis -- Section 3: Enhancing anti-mycobacterial mechanisms -- Chapter 6: Autophagy as a target for host-directed therapy against tuberculosis -- Chapter 7: Metformin: a leading HDT candidate for TB -- Chapter 8: Statins as host-directed therapy for tuberculosis -- Chapter 9: Antimycobacterial attributes of mitochondria: An insight into host defense mechanisms -- Section 4: Targeting immune cells -- Chapter 10: Conventional and unconventional lymphocytes in immunity against Mycobacterium tuberculosis -- Chapter 11: Targeting inhibitory cells such as Tregs and MDSCs in the tuberculous granuloma -- Chapter 12: Targeting suppressor T cells -- Chapter 13: Neutrophil-mediated mechanisms as targets for host-directed therapies against tuberculosis -- Chapter 14: Type I interferon and interleukin-1 driven inflammatory pathways as targets for HDT in tuberculosis -- Chapter 15: Mucosal-associated invariant and Vγ9Vδ2 T cells -- Chapter 16: Airway epithelial cells.-Section 5: Preclinical models for assessing HDTs -- Chapter 17: In vitro models of human granuloma formation to analyze host-directed therapies -- Chapter 18: C3HeB/FeJ as a key mouse strain for testing host-directed therapies against tuberculosis -- Chapter 19: The Rabbit Model for Assessing Host-Directed Therapies for Tuberculosis -- Section 6: Clinical trials of HDTs and special considerations for study endpoints -- Chapter 20:Clinical trials of TB-HDT candidates -- Chapter 21:Outcomes for clinical trials of host-directed therapies for tuberculosis -- Chapter 22: Pharmacological considerations for clinical trials of host-directed therapies for tuberculosis.

This book discusses specific immune cell regulatory pathway(s), immune cell types, or other mechanisms involved in host responses to tuberculosis that can be potentially targeted for host-directed therapy (HDT). The pathways/mechanisms investigated are either protective – thus calling for pathway/factor enhancing drugs – or maladaptive – thus calling for pathway/factor inhibitory drugs. Discovery and development (pre-clinical and clinical) of candidate HDT agents will also be elucidated, as well as approaches for HDT of other diseases. The benefit to the reader will derive from learning about the biology of multiple host pathways involved in health and disease, how these pathways are disrupted or dysregulated during tuberculosis, and which druggable targets exist in these pathways. This book provides the reader with a roadmap of current and future directions of HDT against tuberculosis. Since the host pathways/factors involved in protective or maladaptive responses to tuberculosis are not disease-specific, information learned from the context of tuberculosis likely will be relevant to other infectious and non-infectious diseases.

ISBN: 9783030569051

Standard No.: 10.1007/978-3-030-56905-1doiSubjects--Topical Terms:

668393
Infectious Diseases.

LC Class. No.: QR180-189.5

Dewey Class. No.: 616.079

Advances in Host-Directed Therapies Against Tuberculosis
LDR:04699nam a22003975i 4500 001 1050095
003 DE-He213
005 20210814165549.0
007 cr nn 008mamaa
008 220103s2021 sz | s |||| 0|eng d
020 $a 9783030569051 $9 978-3-030-56905-1
024 7 $a 10.1007/978-3-030-56905-1 $2 doi
035 $a 978-3-030-56905-1
050 4 $a QR180-189.5
072 7 $a MJCM $2 bicssc
072 7 $a MED044000 $2 bisacsh
072 7 $a MJCM $2 thema
082 0 4 $a 616.079 $2 23
245 1 0 $a Advances in Host-Directed Therapies Against Tuberculosis $h [electronic resource] / $c edited by Petros C. Karakousis, Richard Hafner, Maria Laura Gennaro.
250 $a 1st ed. 2021.
264 1 $a Cham : $b Springer International Publishing : $b Imprint: Springer, $c 2021.
300 $a XIII, 332 p. 20 illus. $b online resource.
336 $a text $b txt $2 rdacontent
337 $a computer $b c $2 rdamedia
338 $a online resource $b cr $2 rdacarrier
347 $a text file $b PDF $2 rda
505 0 $a Section 1: Introduction -- Chapter 1: Introduction: An overview of host-directed therapies for tuberculosis -- Section 2: Targeting immunometabolism -- Chapter 2: Sirtuin deacetylases: Linking Mycobacterial infection and host metabolism -- Chapter 3:The mammalian target of rapamycin complex 1 (mTORC1): an ally of M. tuberculosis in host cells -- Chapter 4: HIF-1α as a potential therapeutic target for tuberculosis treatment -- Chapter 5: Nuclear receptors in host-directed therapies against tuberculosis -- Section 3: Enhancing anti-mycobacterial mechanisms -- Chapter 6: Autophagy as a target for host-directed therapy against tuberculosis -- Chapter 7: Metformin: a leading HDT candidate for TB -- Chapter 8: Statins as host-directed therapy for tuberculosis -- Chapter 9: Antimycobacterial attributes of mitochondria: An insight into host defense mechanisms -- Section 4: Targeting immune cells -- Chapter 10: Conventional and unconventional lymphocytes in immunity against Mycobacterium tuberculosis -- Chapter 11: Targeting inhibitory cells such as Tregs and MDSCs in the tuberculous granuloma -- Chapter 12: Targeting suppressor T cells -- Chapter 13: Neutrophil-mediated mechanisms as targets for host-directed therapies against tuberculosis -- Chapter 14: Type I interferon and interleukin-1 driven inflammatory pathways as targets for HDT in tuberculosis -- Chapter 15: Mucosal-associated invariant and Vγ9Vδ2 T cells -- Chapter 16: Airway epithelial cells.-Section 5: Preclinical models for assessing HDTs -- Chapter 17: In vitro models of human granuloma formation to analyze host-directed therapies -- Chapter 18: C3HeB/FeJ as a key mouse strain for testing host-directed therapies against tuberculosis -- Chapter 19: The Rabbit Model for Assessing Host-Directed Therapies for Tuberculosis -- Section 6: Clinical trials of HDTs and special considerations for study endpoints -- Chapter 20:Clinical trials of TB-HDT candidates -- Chapter 21:Outcomes for clinical trials of host-directed therapies for tuberculosis -- Chapter 22: Pharmacological considerations for clinical trials of host-directed therapies for tuberculosis.
520 $a This book discusses specific immune cell regulatory pathway(s), immune cell types, or other mechanisms involved in host responses to tuberculosis that can be potentially targeted for host-directed therapy (HDT). The pathways/mechanisms investigated are either protective – thus calling for pathway/factor enhancing drugs – or maladaptive – thus calling for pathway/factor inhibitory drugs. Discovery and development (pre-clinical and clinical) of candidate HDT agents will also be elucidated, as well as approaches for HDT of other diseases. The benefit to the reader will derive from learning about the biology of multiple host pathways involved in health and disease, how these pathways are disrupted or dysregulated during tuberculosis, and which druggable targets exist in these pathways. This book provides the reader with a roadmap of current and future directions of HDT against tuberculosis. Since the host pathways/factors involved in protective or maladaptive responses to tuberculosis are not disease-specific, information learned from the context of tuberculosis likely will be relevant to other infectious and non-infectious diseases.
650 2 4 $a Infectious Diseases. $3 668393
650 0 $a Pharmacotherapy. $3 973587
650 0 $a Infectious diseases. $3 1102043
650 0 $a Immunology. $3 592892
700 1 $a Gennaro, Maria Laura. $e editor. $4 edt $4 http://id.loc.gov/vocabulary/relators/edt $3 1354343
700 1 $a Hafner, Richard. $e editor. $4 edt $4 http://id.loc.gov/vocabulary/relators/edt $3 1354342
700 1 $a Karakousis, Petros C. $e editor. $4 edt $4 http://id.loc.gov/vocabulary/relators/edt $3 1354341
710 2 $a SpringerLink (Online service) $3 593884
773 0 $t Springer Nature eBook
776 0 8 $i Printed edition: $z 9783030569044
776 0 8 $i Printed edition: $z 9783030569068
776 0 8 $i Printed edition: $z 9783030569075
856 4 0 $u https://doi.org/10.1007/978-3-030-56905-1
912 $a ZDB-2-SBL
912 $a ZDB-2-SXB
950 $a Biomedical and Life Sciences (SpringerNature-11642)
950 $a Biomedical and Life Sciences (R0) (SpringerNature-43708)